JP2018502080A - デングウイルスワクチン組成物およびその使用方法 - Google Patents

デングウイルスワクチン組成物およびその使用方法 Download PDF

Info

Publication number
JP2018502080A
JP2018502080A JP2017533387A JP2017533387A JP2018502080A JP 2018502080 A JP2018502080 A JP 2018502080A JP 2017533387 A JP2017533387 A JP 2017533387A JP 2017533387 A JP2017533387 A JP 2017533387A JP 2018502080 A JP2018502080 A JP 2018502080A
Authority
JP
Japan
Prior art keywords
dengue
vaccine
composition
virus
live
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017533387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502080A5 (https=
Inventor
カジミーロ，ダニーロ・アール
ベット，アンドリュー
コラー，ベス−アン・グリスウォールド
ダナセカラーン，ガバインダラジャン
シンタラ，ラメシュ・ブイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2018502080A publication Critical patent/JP2018502080A/ja
Publication of JP2018502080A5 publication Critical patent/JP2018502080A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017533387A 2014-12-22 2015-12-18 デングウイルスワクチン組成物およびその使用方法 Pending JP2018502080A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095331P 2014-12-22 2014-12-22
US62/095,331 2014-12-22
PCT/US2015/066549 WO2016106107A2 (en) 2014-12-22 2015-12-18 Dengue virus vaccine compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2018502080A true JP2018502080A (ja) 2018-01-25
JP2018502080A5 JP2018502080A5 (https=) 2019-01-31

Family

ID=56151628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533387A Pending JP2018502080A (ja) 2014-12-22 2015-12-18 デングウイルスワクチン組成物およびその使用方法

Country Status (16)

Country Link
US (1) US10449243B2 (https=)
EP (1) EP3236997B1 (https=)
JP (1) JP2018502080A (https=)
CN (1) CN106999568A (https=)
AU (1) AU2015369875A1 (https=)
BR (1) BR112017013270A2 (https=)
CL (1) CL2017001595A1 (https=)
CO (1) CO2017005830A2 (https=)
CR (1) CR20170280A (https=)
ES (1) ES2981476T3 (https=)
MX (1) MX383329B (https=)
MY (1) MY192543A (https=)
NI (1) NI201700080A (https=)
PH (1) PH12017501165B1 (https=)
SG (1) SG11201704942QA (https=)
WO (1) WO2016106107A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143817A1 (en) * 2015-11-20 2017-05-25 Oregon Health & Science University Dengue virus vaccine
TWI625393B (zh) * 2016-11-15 2018-06-01 國立清華大學 對抗複數種登革熱病毒血清型之疫苗套組及其製備方法與用途
WO2019112921A1 (en) 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
WO2020236973A1 (en) * 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines
WO2025027616A1 (en) * 2023-08-01 2025-02-06 Serum Institute Of India Private Limited Freeze-dried viral vaccine compositions and method of manufacturing thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100104598A1 (en) * 2006-08-15 2010-04-29 The Government Of The U.S.A., As Represented By The Secretary, Dept. Of Health Development of dengue virus vaccine components
JP2013542224A (ja) * 2010-10-29 2013-11-21 メルク・シャープ・アンド・ドーム・コーポレーション デングウイルス組換えサブユニットスワクチン
WO2014016362A1 (en) * 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6190859B1 (en) 1995-04-17 2001-02-20 The United States Of America As Represented By The Secretary Of The Army Method and kit for detection of dengue virus
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP0836090A1 (en) 1996-10-12 1998-04-15 Evotec BioSystems GmbH Method of analysis of samples by determination of the distribution of specific brightnesses of particles
EP0977587B1 (en) 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
WO1999006068A2 (en) 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
AU774045B2 (en) 1998-09-02 2004-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Dengue viruses that are replication defective in mosquitos for use as vaccines
EP1165127B1 (en) 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
WO2000057909A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱１型ウイルスワクチン
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
CA2966716C (en) 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
ATE481982T1 (de) 2002-05-03 2010-10-15 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
CA2549173A1 (en) 2003-12-08 2005-07-07 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
CA2611954C (en) 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
CN101238144B (zh) 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
CA2612047C (en) 2005-06-24 2015-05-12 Intervet International B.V. Inactivated chimeric vaccines and related methods of use
CA2616026A1 (en) 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
AR061197A1 (es) 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
ES2517615T3 (es) 2006-11-09 2014-11-03 The United States Of America As Represented By The Secretary Of The Navy Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
US8440202B2 (en) 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
BRPI0904020B8 (pt) * 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
WO2012065105A2 (en) * 2010-11-12 2012-05-18 Thomas Monath Chimeric flavivirus vaccines
JP2016523251A (ja) * 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100104598A1 (en) * 2006-08-15 2010-04-29 The Government Of The U.S.A., As Represented By The Secretary, Dept. Of Health Development of dengue virus vaccine components
JP2013542224A (ja) * 2010-10-29 2013-11-21 メルク・シャープ・アンド・ドーム・コーポレーション デングウイルス組換えサブユニットスワクチン
WO2014016362A1 (en) * 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection

Also Published As

Publication number Publication date
EP3236997A4 (en) 2018-05-30
MX2017008342A (es) 2017-10-24
US10449243B2 (en) 2019-10-22
BR112017013270A2 (pt) 2018-03-06
ES2981476T3 (es) 2024-10-09
MY192543A (en) 2022-08-26
EP3236997A2 (en) 2017-11-01
CR20170280A (es) 2017-08-21
WO2016106107A3 (en) 2016-08-18
NI201700080A (es) 2017-07-18
US20170360917A1 (en) 2017-12-21
PH12017501165B1 (en) 2023-02-22
CL2017001595A1 (es) 2018-01-26
MX383329B (es) 2025-03-13
WO2016106107A2 (en) 2016-06-30
AU2015369875A1 (en) 2017-06-15
EP3236997B1 (en) 2024-05-29
SG11201704942QA (en) 2017-07-28
PH12017501165A1 (en) 2017-12-11
CO2017005830A2 (es) 2017-08-31
CN106999568A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
US12208135B2 (en) Formulations of dengue virus vaccine compositions
JP6018575B2 (ja) デングウイルス組換えサブユニットスワクチン
JP5227172B2 (ja) デングウイルス感染に対するワクチン接種
US10039820B2 (en) West nile virus vaccine comprising WN-80E recombinant subunit protein
US9861692B2 (en) Dengue virus vaccine compositions and methods of use thereof
US10449243B2 (en) Dengue virus vaccine compositions and methods of use thereof
CN103179983B (zh) 重组亚单位登革病毒疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200609